IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...

Over the past year, many IQVIA Holdings Inc. ( NYSE:IQV ) insiders sold a significant stake in the company which ...

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on IQVIA Holdings (IQV – Research Report). The ...

Shares of IQVIA Holdings Inc. IQV slipped 1.12% to $199.11 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 ...

BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...

While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for ...

Makers of drugs and medical devices say the tariffs on goods from Canada, Mexico and China could have an outsized impact on ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

Lupin receives tentative USFDA approval for its generic HIV treatment, combining Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide. The drug, equivalent to Janssen's Symtuza, has ...

IQVIA Holdings Inc. closed 22.27% below its 52-week high of $261.73, which the company achieved on March 8th.